Trial Profile

A Phase Ia Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI345 in Patients With CLDN18.2-positive Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IBI 345 (Primary)
Indications Gastric cancer; Pancreatic cancer
Focus Adverse reactions
Sponsors Innovent Biologics

Most Recent Events

24 Oct 2023 Results (As of Apr 2023, n=5) assessing safety and tolerability, pharmacokinetics and preliminary efficacy of IBI345 presented at the 48th European Society for Medical Oncology Congress.
22 May 2023 Status changed from recruiting to completed.
20 Feb 2022 According to an Innovent Biologics media release, first patient has been dosed in the trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com